Sign inJoin waitlistJoin the waitlist

Binod Dhakal

Professor · Medical College of Wisconsin Affiliated Hospitals, Inc

Credentials: · · · · · ·

History

Medical College of Wisconsin Affiliated Hospitals, Inc
Present

Hematology and Medical Oncology
Medical College of Wisconsin Affiliated Hospitals, Inc
2010–2012
St. Francis Hospital of Evanston
2007–2010
Manipal College of Medical Sciences
1999–2003

Research

Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
New England Journal of Medicine · 2023 · 713 citations
Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma
Journal of Clinical Oncology · 2022 · 224 citations
Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial
The Lancet Haematology · 2023 · 148 citations

Anita D'Souza
88 papers · 1 as a fellow
Parameswaran Hari
80 papers
Saurabh Chhabra
62 papers
Marcelo Pasquini
36 papers
Meera Mohan
35 papers
TF
Timothy Fenske
21 papers
Natalie Callander
20 papers
Luciano Costa
19 papers
Saad Usmani
19 papers
Surbhi Sidana
18 papers
Bhagirathbhai Dholaria
16 papers
Larry Anderson
16 papers

Clinical trials

FT836 CAR T-cell Therapy in Combination With Daratumumab in Patients With Relapsed and/or Refractory Multiple Myeloma
Principal investigator · Not yet recruiting · Phase 1
Medical College of Wisconsin
2026–2030
Phase I Trial of BCMA-TGF-BETA CAR-T Cells in Relapsed, Refractory Myeloma
Principal investigator · Recruiting · Phase 1
Medical College of Wisconsin
2026–2029
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
Principal investigator · Recruiting · Phase 2
C4 Therapeutics, Inc.
2026–2030
Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
Principal investigator · Active not recruiting · Phase 2
Medical College of Wisconsin
2022–2027